Up to date, there have been some approaches making CAR-T cells more persistent and enhanced anti-tumor activity in mouse tumor models, like inhibiting TCR-CD3 complex, CD155, β2-microglobulin, and EZH1, or overexpressing IL-15, IL-15R, and antigen E (Eyquem et al. 2017; Jing et al. 2022; Ueda et al. 2023; Wang et al. 2021). This evidence concerns the gene PVR and neoplasm.